 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 October 1998 | Volume 129 Issue 7 | Pages 559-566
Background: Fludarabine, a purine analogue with activity in chronic lymphocytic leukemia, is usually well tolerated. Although serious infections after fludarabine therapy have been described, a systematic analysis of the risk factors for such infections in chronic lymphocytic leukemia is lacking.
Objective: To determine the risk factors for major infection in patients with chronic lymphocytic leukemia treated with fludarabine.
Design: Retrospective review of medical records.
Setting: Cancer center.
Patients: 402 patients with chronic lymphocytic leukemia not previously treated or treated with chlorambucil (with or without prednisone) who received fludarabine (30 mg/m2 of body surface area per day for 5 days) with or without prednisone at 4-week intervals.
Results: Infections occurred more often in previously treated (144 of 248 [58%]) than in previously untreated (53 of 154 [34%]) patients (P < 0.001). Listeriosis or pneumocystosis occurred in 12 of 170 (7%) previously treated patients receiving fludarabine plus prednisone, 0 of 78 previously treated patients receiving fludarabine alone, and 2 of 154 (1%) previously untreated patients receiving fludarabine plus prednisone (P = 0.003). Univariate analysis identified previous chemotherapy, advanced disease, failure to respond to fludarabine, elevated serum ß2-µglobulin level (P < 0.001), low serum albumin level (P = 0.024), elevated serum creatinine concentration (P = 0.008), and low granulocyte count (P = 0.003) as risk factors for infection. Multivariate analysis identified Rai stage III or IV (odds ratio, 1.98 [95% CI, 1.17 to 3.94]), previous treatment (odds ratio, 2.24 [CI, 1.43 to 3.51]), and elevated serum creatinine concentration (odds ratio, 1.98 [CI, 1.09 to 3.67]) as statistically significant independent risk factors for major infection. A baseline granulocyte count of more than 1000 cells/µL was protective (odds ratio, 0.54 [CI, 0.29 to 0.99]). Five (26%) of 19 patients with a CD4 count less than 50 cells/mL developed cutaneous zoster compared with 9 (6%) of 139 patients with a CD4 count greater than 50 cells/mL (P = 0.01).
Conclusions: Fludarabine used in previously treated patients with chronic lymphocytic leukemia may be associated with infections involving T-cell dysfunction, such as listeriosis, pneumocystosis, mycobacterial infections, and opportunistic fungal and viral infections. Prophylaxis or presumptive therapy should be initiated in the appropriate setting.
CLINICAL REVIEW
Infections in Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine
This article has been cited by other articles:
 |
|
 |
|
  C. Visco, M. Ruggeri, M. Laura Evangelista, R. Stasi, R. Zanotti, I. Giaretta, A. Ambrosetti, D. Madeo, G. Pizzolo, and F. Rodeghiero Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia Blood, February 1, 2008; 111(3): 1110 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Coiffier, S. Lepretre, L. M. Pedersen, O. Gadeberg, H. Fredriksen, M. H. J. van Oers, J. Wooldridge, J. Kloczko, J. Holowiecki, A. Hellmann, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study Blood, February 1, 2008; 111(3): 1094 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Wahlin, B. Sander, B. Christensson, and E. Kimby CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular Lymphoma Clin. Cancer Res., January 15, 2007; 13(2): 388 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Morrison Management of Infectious Complications in Patients with Chronic Lymphocytic Leukemia Hematology, January 1, 2007; 2007(1): 332 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Roberts, M. R. Smith, E. J. Feldman, L. Cragg, M. M. Millenson, G. J. Roboz, C. Honeycutt, R. Thune, K. Padavic-Shaller, W. H. Carter, et al. Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma. Clin. Cancer Res., October 1, 2006; 12(19): 5809 - 5816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sandherr, H. Einsele, H. Hebart, C. Kahl, W. Kern, M. Kiehl, G. Massenkeil, O. Penack, X. Schiel, S. Schuettrumpf, et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO) Ann. Onc., July 1, 2006; 17(7): 1051 - 1059. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Dimopoulou, A. Bamias, P. Lyberopoulos, and M. A. Dimopoulos Pulmonary toxicity from novel antineoplastic agents Ann. Onc., March 1, 2006; 17(3): 372 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Wade Viral Infections in Patients with Hematological Malignancies Hematology, January 1, 2006; 2006(1): 368 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hallek and On Behalf Of The German CLL Study Group Chronic Lymphocytic Leukemia (CLL): First-Line Treatment Hematology, January 1, 2005; 2005(1): 285 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S R Vavricka, J Halter, L Hechelhammer, and A Himmelmann Pneumocystis carinii pneumonia in chronic lymphocytic leukaemia Postgrad. Med. J., April 1, 2004; 80(942): 236 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T. Jones, E. Addison, J. M. North, M. W. Lowdell, A. V. Hoffbrand, A. B. Mehta, K. Ganeshaguru, N. I. Folarin, and R. G. Wickremasinghe Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs Blood, March 1, 2004; 103(5): 1855 - 1861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Velasquez, D. Lew, T. M. Grogan, C. H. Spiridonidis, S. P. Balcerzak, S. R. Dakhil, T. P. Miller, K. S. Lanier, R. A. Chapman, and R. I. Fisher Combination of Fludarabine and Mitoxantrone in Untreated Stages III and IV Low-Grade Lymphoma: S9501 J. Clin. Oncol., May 15, 2003; 21(10): 1996 - 2003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pepper, A. Thomas, T. Hoy, D. Milligan, P. Bentley, and C. Fegan The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro Blood, April 1, 2003; 101(7): 2454 - 2459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. N. Mattiuzzi, J. E. Cortes, M. Talpaz, J. Reuben, M. B. Rios, J. Shan, D. Kontoyiannis, F. J. Giles, I. Raad, S. Verstovsek, et al. Development of Varicella-Zoster Virus Infection in Patients with Chronic Myelogenous Leukemia Treated with Imatinib Mesylate Clin. Cancer Res., March 1, 2003; 9(3): 976 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. O'Brien, N. M.A. Blijlevens, T. H. Mahfouz, and E. J. Anaissie Infections in Patients with Hematological Cancer: Recent Developments Hematology, January 1, 2003; 2003(1): 438 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Helman Jr, J. C. Byrd, N. C. Ales, and A. F. Shorr Fludarabine-Related Pulmonary Toxicity* : A Distinct Clinical Entity in Chronic Lymphoproliferative Syndromes Chest, September 1, 2002; 122(3): 785 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Leporrier, S. Chevret, B. Cazin, N. Boudjerra, P. Feugier, B. Desablens, M.-J. Rapp, J. Jaubert, C. Autrand, M. Divine, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients Blood, October 15, 2001; 98(8): 2319 - 2325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Morrison, K. R. Rai, B. L. Peterson, J. E. Kolitz, L. Elias, F. R. Appelbaum, J. D. Hines, L. Shepherd, R. E. Martell, R. A. Larson, et al. Impact of Therapy With Chlorambucil, Fludarabine, or Fludarabine Plus Chlorambucil on Infections in Patients With Chronic Lymphocytic Leukemia: Intergroup Study Cancer and Leukemia Group B 9011 J. Clin. Oncol., August 15, 2001; 19(16): 3611 - 3621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Hendrick Fatal legionella pneumonia after fludarabine treatment in chronic lymphocytic leukaemia J. Clin. Pathol., May 1, 2001; 54(5): 412 - 413. [Full Text] [PDF]
|
|
|
|
|
|
G. R. Donowitz, D. G. Maki, C. J. Crnich, P. G. Pappas, and K. V.I. Rolston Infections in the Neutropenic Patient-- New Views of an Old Problem Hematology, January 1, 2001; 2001(1): 113 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Robak, J. Z. Blonski, M. Kasznicki, M. Blasinska-Morawiec, E. Krykowski, A. Dmoszynska, H. Mrugala-Spiewak, A. B. Skotnicki, W. Nowak, L. Konopka, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial Blood, October 15, 2000; 96(8): 2723 - 2729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Mauro, R. Foa, R. Cerretti, D. Giannarelli, S. Coluzzi, F. Mandelli, and G. Girelli Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features Blood, May 1, 2000; 95(9): 2786 - 2792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J-F Viallard, P Mercie, I Faure, J-L Pellegrin, and B Leng Successful treatment of lupus with fludarabine Lupus, November 1, 1999; 8(9): 767 - 769. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Kalil and B. D. Cheson Chronic Lymphocytic Leukemia Oncologist, October 1, 1999; 4(5): 352 - 369. [Abstract] [Full Text]
|
|
|
|
|
|
B. D. Cheson, D. A. Vena, J. Barrett, and B. Freidlin Second Malignancies as a Consequence of Nucleoside Analog Therapy for Chronic Lymphoid Leukemias J. Clin. Oncol., August 1, 1999; 17(8): 2454 - 2454. [Abstract] [Full Text] [PDF]
|
|
Article
